Use of direct‐acting oral anticoagulants in solid organ transplantation: A systematic review
AL Bixby, AB Lichvar, D Salerno… - … : The Journal of Human …, 2021 - Wiley Online Library
The use of direct‐acting oral anticoagulants (DOACs) has increased secondary to the
mounting evidence for comparable efficacy and potentially superior safety to vitamin K …
mounting evidence for comparable efficacy and potentially superior safety to vitamin K …
Severe bleeding risk of direct oral anticoagulants versus vitamin K antagonists for stroke prevention and treatment in patients with atrial fibrillation: a systematic review …
W Xu, M Lv, S Wu, S Jiang, Z Zeng, Z Fang… - … Drugs and Therapy, 2023 - Springer
Purpose We aimed to determine the safety of direct oral anticoagulants (DOACs) for stroke
prevention and treatment in patients with atrial fibrillation (AF). Methods A systematic search …
prevention and treatment in patients with atrial fibrillation (AF). Methods A systematic search …
[HTML][HTML] Off-label underdosing or overdosing of non-vitamin K antagonist oral anticoagulants in patients with atrial fibrillation: a meta-analysis
X Wu, L Hu, J Liu, Q Gu - Frontiers in Cardiovascular Medicine, 2021 - frontiersin.org
Background: Several studies have investigated the role of off-label non-vitamin K antagonist
oral anticoagulants (NOACs) in patients with atrial fibrillation (AF). We aimed to compare the …
oral anticoagulants (NOACs) in patients with atrial fibrillation (AF). We aimed to compare the …
Non‐vitamin K antagonist oral anticoagulants versus vitamin K antagonists in atrial fibrillation patients with previous stroke or intracranial hemorrhage: A systematic …
Z Guo, X Ding, Z Ye, W Chen, Y Chen - Clinical Cardiology, 2021 - Wiley Online Library
Several observational studies have compared the effectiveness and safety outcomes
between nonvitamin K antagonist oral anticoagulants (NOACs) and vitamin K antagonists …
between nonvitamin K antagonist oral anticoagulants (NOACs) and vitamin K antagonists …
Direct oral anticoagulants in the treatment of acute venous thromboembolism in patients with obesity: a systematic review with meta-analysis
V Mai, E Marceau-Ferron, L Bertoletti, Y Lacasse… - Pharmacological …, 2021 - Elsevier
Background Direct oral anticoagulants'(DOAC) pharmacokinetics are affected by obesity.
Their efficacy and safety in obesity (BMI≥ 30 kg/m 2) and morbid obesity (BMI≥ 40 kg/m 2) …
Their efficacy and safety in obesity (BMI≥ 30 kg/m 2) and morbid obesity (BMI≥ 40 kg/m 2) …
Safety and efficacy of direct oral anticoagulants in comparison with warfarin across different BMI ranges: A systematic review and meta-analysis
T Almas, F Muhammad, L Siddiqui, B Shafi… - Annals of Medicine …, 2022 - journals.lww.com
Background: Many publications have compared various outcomes defining safety and
efficacy of DOACs across different BMI ranges. Our meta-analysis compares warfarin and …
efficacy of DOACs across different BMI ranges. Our meta-analysis compares warfarin and …
Non-vitamin K antagonist oral anticoagulants versus warfarin in patients with atrial fibrillation and peripheral artery disease: a systematic review and meta-analysis
Background The efficacy and safety of non-vitamin K antagonist oral anticoagulants
(NOACs) compared with warfarin in patients with atrial fibrillation (AF) and peripheral artery …
(NOACs) compared with warfarin in patients with atrial fibrillation (AF) and peripheral artery …
[HTML][HTML] Expert recommendations on the usage of non-vitamin K antagonist oral anticoagulants (NOACs) from India: Current perspective and future direction
Non-vitamin K antagonist oral anticoagulants (NOACs) are a new class of anticoagulant
drugs used in the prevention and treatment of venous thromboembolism (VTE) and atrial …
drugs used in the prevention and treatment of venous thromboembolism (VTE) and atrial …
A retrospective cohort study of the effectiveness and safety of dabigatran versus rivaroxaban in overweight patients with nonvalvular atrial fibrillation
M Yu, Z Wang, L Zong, Q Xu, X Li, Q Lv - International Journal of Clinical …, 2022 - Springer
Background Guidance for dabigatran and rivaroxaban in overweight patients diagnosed
with non-valvular atrial fibrillation (NVAF) is still lacking. Aim Compare the effectiveness and …
with non-valvular atrial fibrillation (NVAF) is still lacking. Aim Compare the effectiveness and …
[HTML][HTML] Comparative effectiveness and safety of direct oral anticoagulants vs warfarin among obese patients with atrial fibrillation
Background Obese patients are underrepresented in clinical trials assessing the
comparative effectiveness and safety of use of direct oral anticoagulants vs use in atrial …
comparative effectiveness and safety of use of direct oral anticoagulants vs use in atrial …